Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review
The DOI matches its Crossref record.
Abstract
Summary: Purpose: Vigabatrin is an efficacious antiepileptic drug licensed as add‐on therapy in refractory epilepsy and used in infantile spasms. Eight years after licensing, there emerged a strong and possibly causative association with bilateral visual field loss. We report a systematic review ascertaining the magnitude of risk of vigabatrin associated visual field loss (VAVFL) and any clinical predictors of risk. Methods: Electronic searches, including MEDLINE (1966–2009), EMBASE (1974–2009), and CINAHL (1982–2009), were conducted. Reports, published in full, of observational studies investigating the prevalence of visual field loss in patients with partial epilepsy treated with vigabatrin were included. Outcomes were the proportion with visual field loss, and the relative risk of VAVFL compared to similar nonexposed patients with epilepsy. Key Findings: Thirty‐two studies were identified, which included 1,678 patients exposed to vigabatrin and 406 controls. Of the 1,678 exposed patients, 738 (44%) had visual field loss compared to just 30 (7%) among the 406 controls. The random‐effects estimate for the proportion of adults with visual field loss was 52% [95% confidence interval (CI) 46–59]. The estimate for children was lower at 34% (95% CI 25–42). The relative risk for field loss in vigabatrin‐exposed patients was 4.0 (95% CI 2.9–5.5). Larger mean cumulative dose of vigabatrin and increasing age were associated with a higher proportion of patients with visual field loss. Significance: Vigabatrin should be reserved for patients with epilepsy for whom there is no other alternative or for patients who have determined the benefit of ongoing treatment to outweigh the risk of VAVFL.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Adverse effects of antiepileptic drugs
Perucca, P., & Gilliam, F. G. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70153-9 · Cited by 694
Mechanisms of Action and Persistent Neuroplasticity by Drugs of Abuse
Korpi, E. R., den Hollander, B., Farooq, U., Vashchinkina, E., Rajkumar, R., Nutt, D. J., Hyytiä, P., & Dawe, G. S. (2015) · Pharmacological Reviews · doi:10.1124/pr.115.010967 · Cited by 148
New GABA modulators protect photoreceptor cells from light-induced degeneration in mouse models
Schur, R. M., Gao, S., Yu, G., Chen, Y., Maeda, A., Palczewski, K., & Lu, Z.-R. (2018) · The FASEB Journal · doi:10.1096/fj.201701250r · Cited by 19
Metadata
- Authors
- Maguire, M. J., Hemming, K., Wild, J. M., Hutton, J. L., & Marson, A. G.
- Venue
- Epilepsia
- Publisher
- Wiley
- Published
- 2010-11-10
- Volume
- 51
- Issue
- 12
- Pages
- 2423-2431
- ISSN
- 0013-9580 (ISSN-L)
- 1528-1167
- OpenAlex
- W1948601338
- Cited by
- 159
- References
- 0
- FWCI
- 3.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review. https://app.cochat.ai/papers/10.1111/j.1528-1167.2010.02772.x
- The paper
- Maguire, M. J., Hemming, K., Wild, J. M., Hutton, J. L., & Marson, A. G. (2010). Prevalence of visual field loss following exposure to vigabatrin therapy: A systematic review. Epilepsia. https://doi.org/10.1111/j.1528-1167.2010.02772.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.